Thomas Von Erlach
Co-Founder & Chief Executive Officer Vivtex Corp.
Thomas von Erlach, PhD co-founded Vivtex and joined as its Chief Scientific Officer when Vivtex was formed as a MIT spin-off in 2018. Prior to that he led the interdisciplinary efforts around gastrointestinal model systems for oral drug delivery applications at the Laboratory of Prof. Robert Langer and Prof. Giovanni Traverso at MIT. Dr von Erlach obtained his PhD from Imperial College London in Bioengineering and a BSc and MSc in Biochemistry and Biotechnology from ETH Zurich in Switzerland. His research interest include advanced in vitro models for drug development, oral drug delivery and gastrointestinal pharmacology. His work is published in several high impact journals such as Nature Materials, Nature Biomedical Engineering, and Nature Communications.
Seminars
- Explore how high-throughput GI permeability and stability screening platforms accelerate lead selection and optimal drug delivery system to maximise oral bioavailability.
- Understand the complex relationship between peptide API structure and drug delivery systems affecting oral exposure.
- Discover how integrating high throughput screening with computational tools can advance lead selection and rapid identification of optimal drug delivery system.
- Assessment potential of AI-ML enabled tools leveraging multidimensional data (permeability, stability, dissolution, and oral PK) to accelerate the development of peptide APIs and formulations optimised for maximal oral exposure.
